KZA.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (13 lapkr. 2023 @ 07:10):

Stats
Dzisiejszy wolumen	454 181
Średni wolumen	473 092
Kapitalizacja rynkowa	18.91M
EPS	$0 ( 2024-02-28 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.727
ATR14	$0.00800 (10.00%)

Wolumen Korelacja

Długi: -0.67 (moderate negative)

Krótki: 0.15 (neutral)

Signal:(43.949) Neutral

Kazia Therapeutics Ltd Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kazia Therapeutics Ltd Korelacja - Waluta/Towar

-0.60
( weak negative )

0.20
( neutral )

0.00
( neutral )

-0.52
( weak negative )

0.63
( weak )

Kazia Therapeutics Ltd Finanse

Annual	2022
Przychody:	$555.00
Zysk brutto:	$555.00 (100.00 %)
EPS:	$-0.110

FY	2022
Przychody:	$555.00
Zysk brutto:	$555.00 (100.00 %)
EPS:	$-0.110

FY	2022
Przychody:	$0
Zysk brutto:	$0 (0.00 %)
EPS:	$-0.190

FY	2021
Przychody:	$15.18M
Zysk brutto:	$0.00 (0.00 %)
EPS:	$-0.0716

Financial Reports:

No articles found.

Kazia Therapeutics Ltd

Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. The company was incorporated in 1994 and is based in Sydney, Australia.